Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
15
×
immunotherapy
15
×
life sciences
national blog main
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
fda
novartis
pfizer
amgen
bristol-myers squibb
cancer
merck
abbvie
cancer immunotherapy
gilead sciences
glaxosmithkline
What
bio
roundup
cancer
drug
annual
medical
companies
conference
days
new
society
approval
approved
ash
biggest
biotech
celgene
clinical
disease
esmo
european
industry
lung
market
medicine
nash
news
oncology
patients
pfizer
price
time
today
abbvie’s
according
acquisitions
advantages
agency
ahead
aimmune
Language
unset
unknown
Current search:
immunotherapy
×
biotech
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@Primary_Immune
6 years ago
Personas Behind One of 2017's Biggest Medical Breakthroughs http://scopeblog.stanford.edu/2017/12/13/a-very-hopeful-job-saving-the-sickest-kids-with-a-new-leukemia-therapy/ #ITRTG #OpenScience #genomics #leukemia #ChildhoodCancer #RareDisease #OpenScience #BigData #biotech #immunotherapy #science #technology https://t.co/zzUP1ZFSoG